Climb Bio (CLYM) Projected to Post Earnings on Wednesday

Climb Bio (NASDAQ:CLYM) will likely be announcing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 7:00 AM ET.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.06). On average, analysts expect Climb Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Climb Bio Stock Performance

Shares of NASDAQ:CLYM opened at $11.45 on Wednesday. The company has a fifty day moving average of $7.66 and a 200-day moving average of $4.93. The company has a market capitalization of $546.97 million, a PE ratio of -12.87 and a beta of 0.02. Climb Bio has a 52-week low of $1.13 and a 52-week high of $11.49.

Hedge Funds Weigh In On Climb Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. MPM Bioimpact LLC bought a new position in shares of Climb Bio during the 4th quarter worth about $10,686,000. Price T Rowe Associates Inc. MD lifted its position in Climb Bio by 265.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock valued at $7,695,000 after acquiring an additional 1,396,722 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in Climb Bio by 972.8% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock valued at $5,730,000 after acquiring an additional 1,298,945 shares in the last quarter. Sphera Funds Management LTD. lifted its position in Climb Bio by 114.4% in the 4th quarter. Sphera Funds Management LTD. now owns 932,247 shares of the company’s stock valued at $3,729,000 after acquiring an additional 497,410 shares in the last quarter. Finally, Shay Capital LLC lifted its position in Climb Bio by 107.5% in the 2nd quarter. Shay Capital LLC now owns 415,000 shares of the company’s stock valued at $515,000 after acquiring an additional 215,000 shares in the last quarter. Institutional investors own 69.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CLYM. Piper Sandler began coverage on Climb Bio in a report on Friday, February 13th. They issued an “overweight” rating for the company. Wedbush began coverage on Climb Bio in a report on Thursday, March 5th. They issued an “outperform” rating and a $12.00 price objective for the company. B. Riley Financial began coverage on Climb Bio in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of Climb Bio in a research report on Wednesday, April 8th. Finally, Chardan Capital began coverage on shares of Climb Bio in a research report on Tuesday. They set a “buy” rating and a $22.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $17.30.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.